Clinical Trials Logo

Acute Chest Syndrome clinical trials

View clinical trials related to Acute Chest Syndrome.

Filter by:

NCT ID: NCT01041339 Completed - Clinical trials for Acute Chest Syndrome

ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?

Start date: January 2010
Phase: N/A
Study type: Observational

A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction. A test of clinical potential if proven to be able to support either origin of acute chest pain etiology.

NCT ID: NCT00951808 Completed - Sickle Cell Disease Clinical Trials

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

PROACTIVE
Start date: July 2009
Phase: N/A
Study type: Interventional

Acute chest syndrome (ACS) is similar to severe pneumonia and is a common cause of hospitalizations for people with sickle cell disease (SCD). Blood transfusions are one treatment option for ACS. High levels of an enzyme called secretory phospholipase A2 (sPLA2) may be present in people before they develop ACS. This study will determine how well sPLA2 levels can predict the onset of ACS and whether identifying high sPLA2 levels allows enough time to prevent ACS with blood transfusions. Results from this study will help to determine the feasibility of conducting a larger study that would further examine the use of sPLA2 levels and blood transfusions to prevent ACS in people with SCD.

NCT ID: NCT00748423 Completed - Sickle Cell Disease Clinical Trials

Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)

INOSTA
Start date: December 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Acute chest syndrome (ACS) is a frequent and potentially life-threatening pulmonary illness. It is a complication of sickle cell disease and is the leading cause of death from this disease in adults. Several pathologic processes are recognized causes of ACS, including infectious diseases, hypoventilation secondary to chest pain, in situ thrombosis and pulmonary fat embolism. Inhaled nitric oxide (iNO) has been shown to be a pulmonary vasodilatator with minimal systemic effects and has also been shown to improve gas exchange in both animal and human acute lung injury (ALI). The combined effects of iNO gas of improving pulmonary ventilation to perfusion matching, reducing alveolar and systemic inflammation, modulate the course of acute chest syndrome, which combine the physiopathology of vaso-occlusive crisis and acute lung injury. We hypothesise inhaled NO will improve oxygenation and clinical outcome of sickle cell disease patients with acute chest syndrome.

NCT ID: NCT00448370 Completed - Anemia, Sickle Cell Clinical Trials

Role of Placenta Growth Factor in Sickle Acute Chest Syndrome

Start date: March 2007
Phase: N/A
Study type: Observational

The purpose of this research study is to find out whether Placenta Growth Factor (PlGF) and related tests can predict the development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) during a period where patients are well and during admission to the hospital for an acute sickle event to see if these measures can predict the development of ACS. Understanding events precipitating ACS may lead to preventative and interventional therapies which will improve patient outcomes and quality of life.

NCT ID: NCT00434473 Completed - Sickle Cell Disease Clinical Trials

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The study will be conducted at 15-20 US centers in a randomized, placebo-controlled, double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC), fever (T ≥38.0°C) and serum sPLA2 concentration ≥50 ng/mL.

NCT ID: NCT00029731 Completed - Pneumonia Clinical Trials

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

Start date: August 2001
Phase: Phase 2
Study type: Interventional

This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of arginine in the body and how the body uses nitric oxide in ACS.